LifeMD, Inc.

Novo Nordisk A/S

Shares of telemedicine platform LifeMD <a href="https://finance.yahoo.com/quote/LFMD/">plunged</a>&nbsp;25% in early trading this morning, November 18. The company’s quarterly results came in weaker than Wall Street expected, and the management also lowered its revenue outlook for the year. The stock was not supported even by an agreement with Novo Nordisk that LifeMD <a href="https://ir.lifemd.com/press-release-details.php?newsId=3189112#:~:text=%D1%8D%D1%82%D0%BE%20%D1%81%D0%B0%D0%BC%D0%B0%D1%8F%20%D0%BD%D0%B8%D0%B7%D0%BA%D0%B0%D1%8F%20%D1%86%D0%B5%D0%BD%D0%B0%20%D0%BD%D0%B0%D0%BB%D0%B8%D1%87%D0%BD%D1%8B%D0%BC%D0%B8%20%D0%B2%20%D1%81%D1%82%D1%80%D0%B0%D0%BD%D0%B5%20%E2%80%94%20%D0%B7%D0%B0%20%D0%B4%D0%B2%D0%B5%20%D0%BF%D0%BE%D0%BA%D1%83%D0%BF%D0%BA%D0%B8%20%D0%B4%D0%BB%D1%8F%20%D0%BD%D0%BE%D0%B2%D1%8B%D1%85%20%D0%BF%D0%B0%D1%86%D0%B8%D0%B5%D0%BD%D1%82%D0%BE%D0%B2.">announced</a>&nbsp;earlier in the day yesterday. Under its terms, the platform will sell the pharma giant’s best-selling drugs Wegovy and Ozempic at “the lowest cash-pay pricing available nationwide.”

LifeMD stock down 25% as worsening outlook overshadows Novo Nordisk partnership news

Eli Lilly and Company

Hims & Hers Health, Inc.

The company is vying for a market that is predicted to grow to $100 billion by the end of the decade

Novo has lowered prices for obesity drugs in the US. This is a new challenge for Eli Lilly

Gubra A/S

Zealand Pharma A/S

The securities of European makers of weight-loss drugs rose sharply this week as investors began rotating capital out of artificial intelligence-related tech stocks and into the health care sector, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-11-14/european-obesity-stocks-join-healthcare-rally-as-ai-trade-ebbs">wrote</a>.

In Europe, investors are leaving the AI sector for healthcare. Which stocks are on the upside?

The company struck a deal with the White House last week: its obesity drugs will be included in Medicare coverage

Eli Lilly shares hit a record for the first time in more than a year. Are they worth buying?

Metsera, Inc.

Pfizer Inc.

Shares in Novo Nordisk, maker of popular obesity drugs Wegovy and Ozempic, rose 2.4% in Copenhagen trading after it pulled <a href="https://www.globenewswire.com/news-release/2025/11/08/3184043/0/en/Novo-Nordisk-will-not-increase-its-proposal-to-acquire-Metsera-Inc.html">out</a> of the race to buy U.S. healthcare startup Metsera.

Novo stock jumped after it lost a battle for a med-startup. What's the upside?

NVIDIA Corporation

Taiwan Semiconductor Manufacturing Company Limited

Visa Inc.

Mastercard Incorporated

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: Investors hope for a speedy end to the shutdown

Developers of diabetes and obesity drugs Eli Lilly and Novo Nordisk have reached agreements with the administration of US President Donald Trump, the two <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916450">companies</a> <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines">announced on</a> November 6. Under the terms of the deal, the pharmaceutical manufacturers will reduce the prices of their popular drugs.

Lilly and Novo will cut the price of obesity drugs in the US. What will they get in return?

Competition with Eli Lilly and abrupt changes in Novo Nordisk's management are putting pressure on its performance

Ozempic's creator lowered forecasts for the fourth time this year. Should we sell the stock?

Novo Nordisk, the maker of obesity drugs Wegovy and Ozempic, and US pharma company Pfizer have improved their offers to buy US startup Metsera, which develops weight-loss drugs. The company itself still considers Novo's offer "more favorable" despite the escalating battle for the deal, the Financial Times <a href="https://www.ft.com/content/ab202cb5-ee27-4257-b2ee-431408c970c1">writes</a>.

Novo Nordisk and Pfizer raise stakes in battle for weight loss drug developer

Pharma companies squabble over a promising startup in the market for weight management products

Pfizer sues Novo Nordisk and Metsera - Oninvest

Danish Novo Nordisk will release its quarterly report on Nov. 5.